

Takeda partners with Engitix to to develop new anti-fibrotic therapies

14 April 2022 | News

Collaboration combines Engitix's unique human extracellular matrix (ECM) platform with Takeda's expertise in gastroenterology research and development (R&D) and commercialisation



UK's Engitix, a biotechnology company developing a portfolio of programmes in fibrosis and solid tumours using its proprietary human extracellular matrix (ECM) platform, entered into an agreement with Japan's Takeda to expand an existing collaboration to now include the discovery and development of novel therapeutics for fibrostenotic inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis.

Under the terms of this agreement, Engitix and Takeda will collaborate in the confirmation and validation of targets and the preclinical development of therapeutics in IBD using Engitix's unique extracellular matrix (ECM) discovery platform.

Takeda will have exclusive rights to develop and commercialise certain clinical candidates generated against validated targets arising from the collaboration. Engitix will receive an upfront payment, with additional near-term payments based on the confirmation and functional validation of selected targets. Engitix will be eligible to receive a total of up to approximately \$300 million for the achievement of preclinical, development, regulatory and commercial milestones over the course of the partnership, as well as further royalty payments based on sales of commercialised products. This agreement builds on the collaboration between the companies announced in mid-2020 for the discovery and development of novel therapeutics for advanced fibrotic liver diseases, including non-alcoholic steatohepatitis (NASH).